Decompensated hepatitis B cirrhosis patients
Conditions
Interventions
TDF cohort:Nil
ETV cohort:Nil
Sponsors
Beijing You'an Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Antiviral group: (1) Patients with decompensated hepatitis B cirrhosis were diagnosed according to the diagnostic criteria of liver cirrhosis diagnosis and treatment guidelines issued by hepatology branch of Chinese Medical Association in 2019; (2) In our hospital, regular follow-up can obtain more complete follow-up data of patients; (3) Patients who had not been treated with entecavir, tenofovir or telbivudine before or within half a year showed positive HBsAg and HBV DNA > 102 IU / ml (Cabos E601, Roche diagnosis, Germany). The long-term medication records can be found in the medical record database of our hospital, and the regular medication for 2 years. Before using nucleoside (acid) analogues, the patients had informed consent. (4) Aged 18 to 80 years old. 2. Non antiviral group: (1) Patients with decompensated hepatitis B cirrhosis were diagnosed according to the diagnostic criteria of liver cirrhosis diagnosis and treatment guidelines issued by hepatology branch of Chinese Medical Association in 2019; (2) Patients with complete follow-up data can be obtained by regular follow-up in our hospital; (3) Patients who had not taken antiviral drugs and had a survival time of at least 6 months; (4) Aged 18 to 80 years old.
Exclusion criteria
Exclusion criteria: 1. Patients with other hepatitis virus infection (such as HAV, HCV, HEV, EBV, etc.); 2. Patients who use hepatotoxic drugs for a long time (such as anti-tumor, anti tuberculosis, nervous system drugs, etc.); 3. Patients with primary or metastatic liver cancer; 4. Patients who have stopped taking antiviral therapy for more than 6 months; 5. Patients with uncontrolled cardiovascular, respiratory, digestive, neurological, urinary and other serious diseases; 6. Pregnant or lactating women; 7. Patients with decompensated liver cirrhosis complicated with alcoholic liver disease; 8. Patients with chronic liver failure or acute attack when child Pugh score is greater than 14; 9. Patients considered by other researchers not to meet the study conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hepatocellular carcinoma; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV DNA; | — |
Countries
China
Contacts
Public ContactHuiguo Ding
Beijing You'an Hospital Affiliated to Capital Medical University
Outcome results
None listed